Concepedia

Scot Ebbinghaus

SE

Statistics

Publications

87

Citations

27.1K

H-Index

45

Active since

1993

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

University of California, Los Angeles

Institut Gustave Roussy

Dana-Farber Cancer Institute

University of California, San Francisco

Scot Ebbinghaus is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in oncology, medicine, and cancer immunotherapy.

Publications per year

1993–2023

87

Publications

87

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Caroline Robert, Jacob Schachter, Georgina V. Long et al. · New England Journal of Medicine · 2015 · 5.8K citations · Full text

, , +17

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

Omid Hamid, Caroline Robert, Adil Daud et al. · New England Journal of Medicine · 2013 · 3.4K citations · Full text

, , +17

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

Andrew X. Zhu, Richard S. Finn, Julien Edeline et al. · The Lancet Oncology · 2018 · 2.5K citations

, , +11

Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial

Richard S. Finn, Baek‐Yeol Ryoo, Philippe Merle et al. · Journal of Clinical Oncology · 2019 · 1.8K citations

, , +13

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

Caroline Robert, Antoni Ribas, Jedd D. Wolchok et al. · The Lancet · 2014 · 1.8K citations

, , +17

1–5 of 87